SynAct Pharma AB SYNACT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 7.20
- Day Range
- SEK 7.06–7.30
- 52-Week Range
- SEK 4.98–124.60
- Bid/Ask
- SEK 7.29 / SEK 7.29
- Market Cap
- SEK 300.84 Mil
- Volume/Avg
- 42,440 / 156,756
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 5
- Website
- https://www.synactpharma.se
Comparables
Valuation
|
Metric
|
SYNACT
|
CALTX
|
HNSA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.39 | 19.00 | — |
Price/Sales | — | 5.27 | 12.05 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SYNACT
|
CALTX
|
HNSA
|
|---|---|---|---|
Quick Ratio | 3.00 | 2.85 | 2.57 |
Current Ratio | 3.01 | 3.13 | 2.66 |
Interest Coverage | −281.14 | −5.64 | −7.14 |
Quick Ratio
SYNACT
CALTX
HNSA
Profitability
|
Metric
|
SYNACT
|
CALTX
|
HNSA
|
|---|---|---|---|
Return on Assets (Normalized) | −52.48% | −24.68% | −71.82% |
Return on Equity (Normalized) | −64.95% | −89.92% | — |
Return on Invested Capital (Normalized) | −64.46% | −31.14% | −85.22% |
Return on Assets
SYNACT
CALTX
HNSA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zplchrkjrd | Gvrh | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qvyqgngc | Dbsflf | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fbxrvbzz | Vtlrxx | $107.8 Bil | |
MRNA
| Moderna Inc | Mpywxkq | Qyyp | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Slnjgqfy | Wgj | $22.2 Bil | |
ARGX
| argenx SE ADR | Nzgjyyg | Kkh | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qbmffgb | Fmxcvg | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zzkrvhrp | Ysddmgk | $15.1 Bil | |
INCY
| Incyte Corp | Lbtszcjs | Kvmrwy | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sqsbdmpck | Gxsxxl | $12.7 Bil |